title: Recurrent headaches with visual disturbance.
abstract: Headache, particularly migraine, is the commonest neurological problem with which patients present to general practitioners and neurologists. Episodic migraine affects up to 18% of women and 6% of men. Acute migraine attacks can be severely disabling and chronic migraine is even more disabling. Of the mental and neurological disorders, migraine ranks eighth worldwide in terms of disability. Migraine is one of the primary headaches and may occur with or without aura. Differentiation from other severe primary headaches, such as cluster headache, is important for management. The vast majority of patients with migraine can be satisfactorily helped and treated. This involves acute and prophylactic drug therapy and management of triggers. In patients with migraine, medication overuse headache and chronic migraine need to be identified and treated.
authors.affiliation: Institute of Neurological Sciences, Prince of Wales Hospital, Sydney, NSW, Australia. a.zagami@unsw.edu.au
authors.forename: Alessandro S
authors.initials: AS
authors.lastname: Zagami
authors.forename: Sian L
authors.initials: SL
authors.lastname: Goddard
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000700:Analgesics / Q000009:adverse effects; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000932:Antiemetics / Q000627:therapeutic use; D003027:Cluster Headache / Q000175:diagnosis; D003937:Diagnosis, Differential; D004878:Ergotamine / Q000627:therapeutic use; D006801:Humans; D008881:Migraine Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000517:prevention & control; D012306:Risk; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D020521:Stroke / Q000209:etiology; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000932:Antiemetics; D004878:Ergotamine; D017367:Selective Serotonin Reuptake Inhibitors; D014662:Vasoconstrictor Agents